Comparing whole body 18 F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer

Yang, Shih-Neng; Liang, Ji An; Lin, Fan; Kao, Chia Hung; Lin, Chin-Chu; Lee, C C

doi:10.1007/s00432-002-0342-5

Cited by 113 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is superior to bone scintigraphy in the detection of bone metastases from lung cancer (sensitivity 92%, specificity 99%), 38 and from BC (sensitivity 95%, specificity 94%). 39 It has lower accuracy in renal and prostate cancer bone metastasis because they are slow growing (so, the uptake of 18-fluorodeoxyglucose is low). 40 PET permits earlier diagnosis of bone metastases in MM, showing bone resorption sites undetected with conventional diagnostic methods.…”

Section: Clinical Aspectsmentioning

confidence: 99%

Bone metastases: an overview

et al. 2017

View full text Add to dashboard Cite

Bone is a frequent site of metastases and typically indicates a short-term prognosis in cancer patients. Once cancer has spread to the bones it can rarely be cured, but often it can still be treated to slow its growth. The majority of skeletal metastases are due to breast and prostate cancer. Bone metastasis is actually much more common than primary bone cancers, especially in adults. The diagnosis is based on signs, symptoms and imaging. New classes of drugs and new interventions are given a better quality of life to these patients and improved the expectancy of life. It is necessary a multidisciplinary approach to treat patients with bone metastasis. In this paper we review the types, clinical approach and treatment of bone metastases.

show abstract

Section: Clinical Aspectsmentioning

confidence: 99%

Bone metastases: an overview

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The early detection of bone metastases has significance in clinical staging, treatment, and prognosis [1,2]; imaging modalities that reveal these metastases, therefore, play an important clinical role. A number of different modalities have proven valuable in the detection of bone metastases; however, all non-invasive techniques currently in use have certain weaknesses [3].…”

Section: Introductionmentioning

confidence: 99%

A comparative study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and 99mTc-MDP whole-body bone scanning for imaging osteolytic bone metastases

et al. 2015

View full text Add to dashboard Cite

BackgroundThe objective of this study was to evaluate the feasibility and diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and 99mTc-methylenediphosphonate (MDP) whole-body bone scanning (BS) for the detection of osteolytic bone metastases.MethodsThirty-four patients with pathologically confirmed malignancies and suspected osteolytic bone metastases underwent 18F-FDG PET/CT and 99mTc-MDP whole-body BS within 30 days. The sensitivity, specificity, and accuracy with respect to the diagnosis of osteolytic bone metastases and bone lesions were compared between the two imaging methods.ResultsThe sensitivity, specificity, and accuracy of 18F-FDG PET/CT for the diagnosis of osteolytic bone metastases were 94.3% (95% confidence interval [CI], 91.6–96.2%), 83.3% (95% CI, 43.6–96.9%), and 94.2% (95% CI, 91.5–96.1%), respectively. It was found that 99mTc-MDP whole-body BS could discriminate between patients with 50.2% (95% CI, 45.4–55.1%) sensitivity, 50.0% (95% CI, 18.8–81.2%) specificity, and 50.2% (95% CI, 45.5–55.1%) accuracy. 18F-FDG PET/CT achieved higher sensitivity, specificity, and accuracy in detecting osteolytic bone metastases than 99mTc-MDP whole-body BS (p<0.001).ConclusionsF-FDG PET/CT has a higher diagnostic value than 99mTc-MDP whole-body BS in the detection of osteolytic bone metastases, especially in the vertebra.

show abstract

“…The standard uptake values (SUVs) obtained with FDG-PET for osteolytic lesions have been reported higher than those obtained for osteoblastic lesions (means of 6.77 and 0.95, respectively; P \ 0.01) [47]. FDG-PET appears to be more specific than scintigraphy, although no significant differences in sensitivity are reported with respect to the detection of bone metastases using radiography, CT, MRI, or bone biopsy in some cases [46,[50][51][52].…”

Section: Detection Of Metastases and Recurrent Diseasementioning

confidence: 98%